FDA approved for Type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Dual GIP/GLP-1 receptor agonist with strong efficacy for glycemic control and weight reduction.
Overview
FDA approved for Type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).
Clinical Effects
Tirzepatide is a cutting-edge medication designed to simultaneously activate GLP-1 and GIP receptors, offering a unique dual-action approach for managing type 2 diabetes and obesity. By significantly enhancing insulin secretion, improving insulin sensitivity, and effectively suppressing appetite, Tirzepatide delivers powerful metabolic benefits including substantial weight loss and superior glycemic control. This innovative dual receptor targeting positions Tirzepatide as a highly promising therapeutic agent in the treatment of metabolic diseases.
Quick Information
Safety Information
Contraindications
Reported side effects are generally mild, primarily involving transient gastrointestinal symptoms such as nausea, vomiting, and decreased appetite. Long-term safety studies continue to be necessary.
Side Effects
Reported side effects are generally mild, primarily involving transient gastrointestinal symptoms such as nausea, vomiting, and decreased appetite. Long-term safety studies continue to be necessary.